Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser

Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02492373

Enrollment

Registered

2015-07-08

Start date

2015-02-28

Completion date

2016-05-31

Last updated

2016-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lentigines, Post Inflammatory Hyperpigmentation

Keywords

Post inflammatory hyperpigmentation, topical high potency steroid, Qs NdYAG laser

Brief summary

To investigate the benefit of the application of topical high potency steroid on the incidence of post inflammatory hyperpigmentation after laser treatment.

Detailed description

* The incidence of post inflammatory hyperpigmentation (PIH) after treating lentigines with Q-switched Nd:YAG laser was 78.3%. * It has been found that the incidence of PIH decreased to 40% after applied topical high potency steroid 2 days after the laser treatment. * By these anti-inflammatory and anti-PIH effects of the high potency steroid, the investigators aimed that the application of steroid 2 days before and 2 days after the laser treatment would be better reduction in the incidence of PIH after Q-switched Nd:YAG laser.

Interventions

DRUGtopical 0.05% Clobetasol propionate ointment

Apply only on the treated area twice a day as mentions

DEVICEQ switched Nd:YAG laser 532 nm

Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Having multiple lentigines on both sides of the face * Fitzpatrick skin phototype 3-5

Exclusion criteria

* Patients with lesions with any clinical suspicion of being pre-cancerous or skin malignancies of any kind * Patients who have photosensitive dermatoses * Pregnancy and lactation woman * Patients with wound infections (herpes, other) on the day of treatment * Patients with moderate and severe inflammatory acne, Immunosuppressed patients, history of vitiligo * Patients with unrealistic concerns/expectations and inability to do the appropriate post-operative care

Design outcomes

Primary

Measure	Time frame	Description
The incidence of post inflammatory hyperpigmentation	2 weeks	By investigator's observation.

Secondary

Measure	Time frame	Description
Side effects of topical steroid	Follow-up 2, 3, 4, 8, 12 and 24 weeks after the last treatment	By investigators' observation of telangiectasia, erythema or atrophy.
The patients satisfaction	Follow-up 4, 8, 12 and 24 weeks after the last treatment	By using Quartile grading scale of improvement; 0 = not improve, 1= 1-25% improvement, 2 = 26-50% improvement, 3 = 51-75% improvement and 4 = 76-100% improvement

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026